Minireview
Pharmacokinetic Considerations in Obesity

https://doi.org/10.1021/js980173aGet rights and content

References and Notes (95)

  • E.A. Lew

    Mortality and weight: Insured lives and the Americal Cancer Society studies

    Ann. Intern. Med.

    (1985)
  • F.X. Pi‐Sunyer

    Medical hazards of obesity

    Ann. Intern. Med.

    (1993)
  • S. Suissa et al.

    Body size and breast cancer prognosis: a statistical explanation of the discrepancies

    Cancer Res.

    (1989)
  • R.T. Seine et al.

    Obesity at diagnosis of breast carcinoma influences duration of disease‐free survival

    Ann. Intern. Med.

    (1992)
  • J. Bastarrachea et al.

    Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer

    Ann. Intern. Med.

    (1994)
  • G. Cheymol

    Clinical pharmacokinetics of drugs in obesity: an update

    Clin Pharmacokinet.

    (1993)
  • R.A. Blouin et al.

    Special pharmacokinetic considerations in the obese

  • G. Cheymol

    Drug pharmacokinetics in the obese

    Fundam. Clin. Pharmacol.

    (1988)
  • R.A. Blouin et al.

    Influence of obesity on drug disposition

    Clin. Pharmacy

    (1987)
  • D.R. Abernethy et al.

    Drug disposition in obese humans: an update

    Clin. Pharmacokinet.

    (1986)
  • D.R. Abernethy et al.

    Alterations in drug distribution and clearance due to obesity

    J Pharmacol. Exp. Ther.

    (1981)
  • G.B. Corcoran et al.

    Pharmacokinetic characteristics of the obese overfed rat model

    Int. J. Obes.

    (1989)
  • D.J. Greenblatt et al.

    Effect of age, gender, and obesity on midazolam kinetics

    Anesthesiology

    (1984)
  • S.L. Bowman et al.

    A comparison of the pharmacokinetics of propanolol in obese and normal volunteers

    Br. J. Clin. Pharmacol.

    (1986)
  • S.M. Flechner et al.

    The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients

    Transplantation

    (1989)
  • G. Cheymol et al.

    The pharmacokinetics of dexfenfluramine in obese and nonobese subjects

    Br. J. Clin. Pharmacol.

    (1995)
  • M. Rowland et al.

    Clinical Pharmacokinetics: Concepts and Applications

    (1989)
  • I.H. Benedek et al.

    Serum alpha1‐acid glycoprotein and the binding of drugs in obesity

    Br. J. Clin. Pharmacol.

    (1983)
  • I.H. Benedek et al.

    Serum protein binding and the role of increased alpha1‐acid glycoprotein in moderately obese male subjects

    Br. J. Clin. Pharmacol.

    (1984)
  • J. Kjellberg et al.

    Body composition in obesity

    Acta Med. Scand.

    (1970)
  • R.L. Naeye et al.

    The sizes and numbers of cells in visceral organs in human obesity

    Am. J. Clin. Pathol.

    (1970)
  • H.L. Smith

    The relation of the weight of the heart to the weight of the body and of the weight of the heart to age

    Am. Heart J.

    (1928)
  • J.K. Alexander et al.

    Blood volume, cardiac output, and disposition of systemic blood flow in extreme obesity

    Cardiovasc. Res. Cent. Bull.

    (1962)
  • J.K. Alexander

    Obesity and cardiac performance

    Am. J. Cardiol.

    (1964)
  • O. de Divitiis et al.

    Obesity and cardiac function

    Circulation

    (1981)
  • G.C. Yee et al.

    Effect of obesity on CSA disposition

    Transplantation

    (1988)
  • D. Jung et al.

    Thiopental disposition in lean and obese patients undergoing surgery

    Anesthesiology

    (1982)
  • D.R. Abernethy et al.

    Prolonged accumulation of diazepam in obesity

    J Clin Pharmacol

    (1983)
  • A. Leo et al.

    Partition coefficients and their uses

    Chem. Rev.

    (1971)
  • R.M. Arendt et al.

    Predicting in vivo benzodiazepine distribution based upon in vitro lipophilicity

    Clin. Pharmacol. Ther.

    (1982)
  • D.R. Abernethy et al.

    Digoxin disposition in obesity: clinical pharmacokinetic investigation

    Am. Heart J.

    (1981)
  • P.B. Christoff et al.

    Procainimide disposition in obesity

    Drug Intell. Clin. Pharm.

    (1983)
  • W.A. Ritchel et al.

    Prediction of apparent volumes of distribution in obesity

    Methods Find Exp Clin Pharmacol

    (1986)
  • J.E. Doherty et al.

    The distribution and concentration of tritiated digoxin in human tissues

    Ann. Intern. Med.

    (1967)
  • T.M. Rohrbaugh et al.

    The effect of obesity on apparent volume of distribution of theophylline

    Pediatr. Pharmacol.

    (1982)
  • P. Gal et al.

    Theophylline disposition in obesity

    Clin. Pharmacol. Ther.

    (1978)
  • A. Rizzo et al.

    Effect of body weight on the volume of distribution of theophylline

    Lung

    (1988)
  • S.N. Schwartz et al.

    A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects

    J Infect. Dis

    (1978)
  • R.A. Blouin et al.

    Tobramycin pharmacokinetics in morbidly obese patients

    Clin. Pharmacol. Ther.

    (1979)
  • L.A. Bauer et al.

    Amikacin pharmacokinetics in morbidly obese patients

    Am. J. Hosp. Pharm.

    (1980)
  • F. Varin et al.

    Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium

    Clin. Pharmacol. Ther.

    (1990)
  • C.L. Le Jeunne et al.

    Pharmacokinetics of intravenous bisoprolol in obese and nonobese volunteers

    Eur. J. Clin. Pharmacol.

    (1991)
  • G. Cheymol et al.

    Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects

    Eur. J. Clin. Pharmacol.

    (1997)
  • D.R. Abernethy et al.

    Phenytoin disposition in obesity

    Arch. Neurol.

    (1985)
  • G. Cheymol

    Comparative pharmacokinetics of intravenous propanolol in obese and normal volunteers

    J. Clin. Pharmacol.

    (1987)
  • C.L. Derry et al.

    Pharmacokinetics and pharmaco‐dynamics of triazolam after two intermittent doses in obese and normal‐weight men

    J. Clin. Psychopharmacol.

    (1995)
  • D.R. Abernethy et al.

    Verapamil pharmacodynamics and disposition in obese hypertensives

    J. Cardiovasc. Pharmacol.

    (1988)
  • Cited by (174)

    • Obesity and impact on gastroesophageal reflux disease

      2022, Obesity and Esophageal Disorders
    • Differential effect of body mass index (BMI) on outcomes of patients treated with docetaxel in prostate cancer - An exploratory analysis.

      2022, Cancer Treatment and Research Communications
      Citation Excerpt :

      The relationship between obesity and cancer is rather [3]. Apart from being a risk factor for cancers, obesity can also alter anticancer drug metabolism, especially that of lipophilic drugs [4,5]. However, there is sparse literature on drug efficacy as a function of adiposity, despite a significant proportion of cancer patients being overweight or obese.

    • The Crashing Obese Patient

      2020, Emergency Medicine Clinics of North America
    View all citing articles on Scopus
    View full text